811669--2/24/2006--UST_INC

related topics
{product, liability, claim}
{financial, litigation, operation}
{product, market, service}
{operation, natural, condition}
{personnel, key, retain}
{cost, regulation, environmental}
The tobacco industry is subject to governmental regulation and other restrictions. In particular, restrictions on tobacco marketing and advertising limit the options available to the Company to market smokeless tobacco products. The excise taxes on smokeless tobacco products could affect consumer preferences and have an adverse effect on the sale of the Company s products. The smokeless tobacco category is highly competitive and the Company s volumes and profitability may be adversely affected by continued consumer down-trading from premium brands to price-value brands or by potential new entrants into the marketplace. The Company has ongoing payment obligations under the Fair and Equitable Tobacco Reform Act, the STMSA and other state settlement agreements. Fluctuations in the price and availability of tobacco leaf could adversely affect the Company s results of operations. Fire, violent weather conditions and other disasters may adversely affect the Company s operations. The Company s continuing ability to hire and retain qualified employees is important to the future success of the Company. The Company is subject, from time to time, to smokeless tobacco and health litigation, which, if adversely determined, could subject the Company to substantial charges and liabilities. The Company could be subject to additional charges and liabilities as it seeks to resolve the remaining antitrust related lawsuits.

Full 10-K form ▸
related documents
862668--9/29/2008--ESCALON_MEDICAL_CORP
780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC
27096--9/13/2006--DATASCOPE_CORP
1000736--3/2/2006--CAREMARK_RX_INC
862668--10/12/2010--ESCALON_MEDICAL_CORP
874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC
810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC
1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP
718924--12/27/2006--SPAN_AMERICA_MEDICAL_SYSTEMS_INC
911649--4/2/2007--STRATEGIC_DIAGNOSTICS_INC/DE/
739944--3/15/2007--MEDTOX_SCIENTIFIC_INC
57528--2/22/2008--LANCE_INC
874734--3/8/2010--OSTEOTECH_INC
811669--2/23/2007--UST_INC
882873--9/21/2009--UROLOGIX_INC
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC
739944--3/17/2006--MEDTOX_SCIENTIFIC_INC
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC
874710--9/28/2006--ALLIED_HEALTHCARE_PRODUCTS_INC
929987--2/22/2006--GUIDANT_CORP
10795--11/24/2010--BECTON_DICKINSON_&_CO
780127--1/12/2006--SYNOVIS_LIFE_TECHNOLOGIES__INC
27096--9/12/2007--DATASCOPE_CORP
10456--2/26/2008--BAXTER_INTERNATIONAL_INC
7536--2/8/2008--ARROW_ELECTRONICS_INC
862668--10/13/2009--ESCALON_MEDICAL_CORP
1110783--10/26/2007--MONSANTO_CO_/NEW/
1114200--2/27/2008--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC
768408--6/24/2010--CYANOTECH_CORP
880432--9/28/2009--MISONIX_INC